Across
- 2. Treatment given before full microbiology results are available
- 5. reassessing need, dose, route & duration of antimicrobial therapy
- 12. Has limited microbial coverage to minimise collateral damage and resistance risk
- 13. Broad-spectrum carbapenem reserved for severe infections
- 15. RNA virus responsible for significant seasonal respiratory infections
- 17. Lab-based input essential to confirm pathogens and optimise antimicrobial therapy.
Down
- 1. Macrolide used for respiratory infections and chlamydia when first-line therapy isn’t appropriate.
- 3. A macrolide antibiotic used where penicillin allergy exists
- 4. Switching to narrower spectrum therapy once culture results are known
- 6. Enteric bacterium commonly associated with UTIs and gastrointestinal disease strains
- 7. Loss of effectiveness of an anti-infective medicine in a microorganism
- 8. Enterobacterales genus associated with pneumonia and UTIs
- 9. Antibiotic commonly used in lower urinary tract infections in primary care
- 10. Resistant S. aureus strain not susceptible to β-lactams
- 11. Organisational or system-wide approach to optimising antimicrobial use
- 14. if suspected, antibiotic therapy should start within 1 hour according to national guidance
- 16. Term inclusive of antibacterial, antiviral, antifungal and antiparasitic agents